glp-1 therapy exercise optimization weight loss therapies like Foundayo™ drive primarily by reducing appetite and energy intake—but this does not guarantee optimal body composition. Weight loss can include reductions in muscle Optimizing GLP-1 therapies for obesity

The hormone not only impacts hunger signals but also improves how effectively the body uses insulin

We need well-designed, long-term studies in people taking GLP-1 drugs that: directly measure skeletal muscle (not just lean mass), assess muscle function and mobility, track outcomes over months to years, not weeks, and test mitigation strategies, not just observe loss

Genetic research has identified markers associated with varying responses to GLP-1 therapy, including variants in the GLP1R gene, GIPR gene, and metabolic regulators like FTO and MC4R

GLP-1 is released from L-cells, most densely located in the distal small intestine and colon, although they are also located more proximally in the duodenum and jejunum (89)